Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-XL: XL092 in Metastatic Castration-Resistant Prostate Cancer
NCT06568562Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Utah. Started Dec 2024; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06568562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568562.